Tagomics introduces LiquiPath, a first-in-class cfDNA-based blood test for multi-organ drug safety monitoring

Tagomics Ltd., a pioneering precision medicine company, today announced the launch of LiquiPath™, a cross-species, multi-organ "liquid pathology" platform, for non-invasive drug safety monitoring.

Read Original Copy